Loxo Oncology CS (LOXO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2016 | 12-2015 | 09-2015 | 06-2015 | 03-2015 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 47,547 | 68,177 | 34,409 | 36,635 | 37,255 |
| Marketable Securities | 97,296 | 85,715 | 59,013 | 65,165 | 60,697 |
| TOTAL | $147,254 | $156,644 | $96,406 | $103,182 | $99,165 |
| Non-Current Assets | |||||
| PPE Net | 303 | 88 | 74 | 78 | 31 |
| Investments And Advances | 0 | 0 | 0 | 0 | 9,650 |
| Other Non-Current Assets | 496 | 726 | 222 | 23 | 23 |
| TOTAL | $799 | $814 | $296 | $101 | $9,704 |
| Total Assets | $148,053 | $157,458 | $96,702 | $103,283 | $108,869 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 758 | 269 | 731 | 415 | 285 |
| Accrued Expenses | 2,147 | 2,584 | 2,108 | 1,403 | 1,024 |
| TOTAL | $2,905 | $2,853 | $2,839 | $1,818 | $1,309 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $2,905 | $2,853 | $2,839 | $1,818 | $1,309 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 19,709 | 19,651 | 16,687 | 16,687 | 16,687 |
| Common Shares | 2 | 2 | 2 | 2 | 2 |
| Retained earnings | -78,435 | -66,838 | -53,971 | -45,200 | -37,144 |
| Other shareholders' equity | 41 | -16 | 7 | 3 | -7 |
| TOTAL | $145,148 | $154,605 | $93,863 | $101,465 | $107,560 |
| Total Liabilities And Equity | $148,053 | $157,458 | $96,702 | $103,283 | $108,869 |